Januvia (Sitagliptin Phosphate) Patent Expiration, LOE Window & CMS Spending

Januvia (Sitagliptin Phosphate) by Merck & Co.: FDA Orange Book core substance LOE 2027-05-24, 3 AB generics, $4.45B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN021995 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-05-24
Last Listed Patent or Exclusivity Date2027-05-24
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$4.45B
2024 Medicare Part D Spend$3.81B
2024 Medicaid Spend$646.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.